Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Pooled analysis of MAIA & ALCYONE data on infections finds incidence higher w/ D-Rd/D-VMP vs Rd/VMP for G3/4 (36.9% vs 22.4%) and G5 (3.0% vs 1.5%) infections but exposure-adjusted incidence rates were generally comparable.”
Title: Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE
Authors: Nizar J. Bahlis, Thierry Facon, Jesús F. San-Miguel, Saad Z. Usmani, Meletios-Athanasios A. Dimopoulos, Philippe Moreau, Sonja Zweegman, Aurore Perrot, Salomon Manier, Ajai Chari, Noopur S. Raje, Robert Z. Orlowski, Hartmut Goldschmidt, Supratik Basu, Cyrille Hulin, Katja C. Weisel, Mohamad Mohty, Xavier Leleu, Torben Plesner, Andrzej J. Jakubowiak, Gordon Cook, Hang Quach, Christopher P. Venner, Michele Cavo, Mai Ngo, Kasey Bolyard, Robin Carson, Fredrik Borgsten, Maria-Victoria Mateos, Shaji K. Kumar
You can read the Full Article in Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
